metoprolol has been researched along with Cirrhosis, Liver in 10 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed the pharmacokinetics of the six compounds and their CYP-specific metabolites of the Basel phenotyping cocktail (CYP1A2: caffeine, CYP2B6: efavirenz, CYP2C9: flurbiprofen, CYP2C19: omeprazole, CYP2D6: metoprolol, CYP3A: midazolam) in patients with liver cirrhosis (n = 16 Child A cirrhosis, n = 15 Child B cirrhosis, n = 5 Child C cirrhosis) and matched control subjects (n = 12)." | 4.12 | Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently. ( Bachmann, F; Bouitbir, J; Duthaler, U; Grandinetti, T; Haschke, M; Hruz, P; Krähenbühl, S; Pfefferkorn, F; Suenderhauf, C, 2022) |
| " Pharmacokinetic and pharmacodynamic changes depend on the nature and degree of hepatic impairment and on the characteristics of the dosed drug." | 2.49 | [Effect of liver cirrhosis on pharmacokinetics and pharmacodynamics of drugs]. ( Perlík, F, 2013) |
| " Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| " Studies were undertaken using an in situ-perfused rat liver and multiple indicator dilution, and outflow data were analyzed with a physiologically based organ pharmacokinetic model." | 1.37 | Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Thorling, CA; Zhang, Q, 2011) |
| " The pharmacokinetic parameters were estimated using previously developed barrier-limited and space-distributed models." | 1.36 | Liver fibrosis impairs hepatic pharmacokinetics of liver transplant drugs in the rat model. ( Asadian, P; Crawford, DH; Fletcher, LM; Khlentzos, AM; Li, P; Liu, X; Roberts, MS; Robertson, TA; Thorling, CA; Zou, YH, 2010) |
| "Metoprolol treatment of hypertensive patients with hepatic cirrhosis resulted in development of bradycardia." | 1.34 | [Pharmacokinetics of enalapril and metoprolol in hypertensive patients with hepatic pathology]. ( Drozdov, VN; Lazebnik, LB; Mikheeva, OM; Petrakov, AV; Sil'vestrova, SIu, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, P | 3 |
| Robertson, TA | 3 |
| Thorling, CA | 2 |
| Zhang, Q | 2 |
| Fletcher, LM | 3 |
| Crawford, DH | 3 |
| Roberts, MS | 3 |
| Duthaler, U | 1 |
| Bachmann, F | 1 |
| Suenderhauf, C | 1 |
| Grandinetti, T | 1 |
| Pfefferkorn, F | 1 |
| Haschke, M | 1 |
| Hruz, P | 1 |
| Bouitbir, J | 1 |
| Krähenbühl, S | 1 |
| Silvestre, OM | 1 |
| Farias, AQ | 1 |
| Ramos, DS | 1 |
| Furtado, MS | 1 |
| Rodrigues, AC | 1 |
| Ximenes, RO | 1 |
| de Campos Mazo, DF | 1 |
| Yoshimura Zitelli, PM | 1 |
| Diniz, MA | 1 |
| Andrade, JL | 1 |
| Strunz, C | 1 |
| Friedmann, AA | 1 |
| Lee, SS | 1 |
| Carrilho, FJ | 1 |
| D'Albuquerque, LAC | 1 |
| Bacal, F | 1 |
| Perlík, F | 1 |
| Zou, YH | 1 |
| Liu, X | 1 |
| Khlentzos, AM | 1 |
| Asadian, P | 1 |
| Weiss, M | 1 |
| Lazebnik, LB | 1 |
| Mikheeva, OM | 1 |
| Drozdov, VN | 1 |
| Petrakov, AV | 1 |
| Sil'vestrova, SIu | 1 |
| Westaby, D | 2 |
| Bihari, DJ | 1 |
| Gimson, AE | 2 |
| Crossley, IR | 1 |
| Williams, R | 2 |
| Bützow, GH | 1 |
| Remmecke, J | 1 |
| Bräuer, A | 1 |
| Melia, WM | 1 |
| Macdougall, BR | 1 |
| Hegarty, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| In Vivo Determination of Cytochrome P450 Activities in Patients With Liver Cirrhosis[NCT03337945] | 48 participants (Actual) | Interventional | 2018-04-04 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metoprolol and Cirrhosis, Liver
| Article | Year |
|---|---|
[Effect of liver cirrhosis on pharmacokinetics and pharmacodynamics of drugs].
Topics: Analgesics; Anesthetics, Local; Anti-Arrhythmia Agents; Antihypertensive Agents; Hepatic Insufficien | 2013 |
4 trials available for metoprolol and Cirrhosis, Liver
| Article | Year |
|---|---|
β-Blocker therapy for cirrhotic cardiomyopathy: a randomized-controlled trial.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Biomarkers; Brazil; Cardiac Output; Cardi | 2018 |
Selective and non-selective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension.
Topics: Cardiac Output; Female; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; Male; Meto | 1984 |
Metoprolol in portal hypertension. A controlled study.
Topics: Adult; Blood Pressure; Cardiac Output; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Liver | 1982 |
B1 selective adrenoreceptor blockade for the long term management of variceal bleeding. A prospective randomised trial to compare oral metoprolol with injection sclerotherapy in cirrhosis.
Topics: Clinical Trials as Topic; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Human | 1985 |
5 other studies available for metoprolol and Cirrhosis, Liver
| Article | Year |
|---|---|
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cations; Cytochrome P-450 | 2011 |
Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.
Topics: Caffeine; Child; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochr | 2022 |
Liver fibrosis impairs hepatic pharmacokinetics of liver transplant drugs in the rat model.
Topics: Animals; Bile Ducts, Intrahepatic; Carbon Tetrachloride; Extracellular Space; Furosemide; Liver; Liv | 2010 |
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
[Pharmacokinetics of enalapril and metoprolol in hypertensive patients with hepatic pathology].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chromatography, High Pressure | 2007 |